



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

28 April 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	175,794	26,585	11,312	7,287	7,280	4,912	5,661	2,746	756
New (1st dose)	21,776	3,725	920	533	1,022	939	445	1,044	203
Total (1st)	2,586,769	406,009	157,866	108,655	126,965	85,729	71,662	46,370	12,764
Total (2nd)	148,282	25,635	7,667	5,101	13,165	4,854	5,258	6,001	1,627
	Total	Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	37,388	7,021	6,687	6,581	13,354	12,178	9,699	14,310	2,037
New (1st dose)	2,815	1,656	1,441	1,424	1,432	1,522	435	1,685	535
Total (1st)	552,818	95,051	97,802	129,342	136,081	154,706	171,838	200,453	32,658
Total (2nd)	22,253	8,718	8,894	7,521	7,855	6,872	3,761	8,917	4,183

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	2,735,051	412	0.53%	392	10	4	6
	Total		14,567		14,293	157	49	68
AstraZeneca	New	1,444,022	305	0.89%	297	8	0	0
	Total		12,814		12,613	128	33	40
Pfizer	New	1,291,029	107	0.14%	95	2	4	6
	Total		1,753		1,680	29	16	28

¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

28 April 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		775 (100)	120,673 (100)	232.75
Sex	Male	381 (49.16)	60,070 (49.78)	232.26
	Female	394 (50.84)	60,603 (50.22)	233.23
Age	80 or above	20 (2.58)	5,270 (4.37)	277.48
	70-79	68 (8.77)	8,745 (7.25)	242.44
	60-69	133 (17.16)	18,574 (15.39)	292.77
	50-59	139 (17.94)	22,356 (18.53)	257.94
	40-49	121 (15.61)	17,854 (14.80)	212.82
	30-39	110 (14.19)	16,232 (13.45)	230.40
	20-29	107 (13.81)	17,999 (14.92)	264.44
	10-19	46 (5.94)	8,439 (6.99)	170.81
0-9	31 (4.00)	5,204 (4.31)	125.44	

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		1 (100)	1,821 (100)	1.51	160 (100)
Sex	Male	0 (0.00)	906 (49.75)	1.51	102 (63.75)
	Female	1 (100.00)	915 (50.25)	1.51	58 (36.25)
Age	80 or above	1 (100.00)	1,002 (55.02)	19.01	38 (23.75)
	70-79	0 (0.00)	521 (28.61)	5.96	54 (33.75)
	60-69	0 (0.00)	212 (11.64)	1.14	45 (28.13)
	50-59	0 (0.00)	62 (3.40)	0.28	13 (8.13)
	40-49	0 (0.00)	14 (0.77)	0.08	8 (5.00)
	30-39	0 (0.00)	7 (0.38)	0.04	1 (0.63)
	20-29	0 (0.00)	3 (0.16)	0.02	1 (0.63)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.15.	4.16.	4.17.	4.18.	4.19.	4.20.	4.21.	4.22.	4.23.	4.24.	4.25.	4.26.	4.27.	4.28.
Total	99	111	108	102	99	109	116	125	127	136	136	132	156	160

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)